Driving Simulation to Assess Non-Sedative Effects of Tolperisone

Status Completed

Clinical Trial Summary

This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.

Clinical Trial Description

This will be a randomized, placebo-controlled, multiple-dose 3-way cross-over study of the safety and cognitive effects of multiple doses of 150 mg tolperisone administered TID in 30 male and female healthy volunteers. Treatment groups include 450 mg tolperisone (i.e., 150 mg administered three times daily), 30 mg cyclobenzaprine (i.e., 10 mg administered three times daily), and placebo. Subjects will receive 3 days of each treatment. Subject participation will be approximately 3 weeks as outpatients with 3 days each week as overnight clinic participants. In this crossover study, treatment effects will be assessed following the second initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3). Subjects will be dosed on the morning of Day 1. Approximately one hour after the second dose on Day 1, subjects will be administered the cognitive test, followed by the driving simulator examination. On the morning of Day 2, prior to dosing, subjects will be readministered the cognitive test and driving examination to assess residual next day effects. Subjects will repeat cognitive testing and the driving examination on the morning of Day 3, after administration of the AM study medication, to evaluate the cumulative effects of 3 days of dosing. ;

Study Design

Related Conditions & MeSH terms

Driving Impaired

Clinical Trial Details

NCT number	NCT03353922
Study type	Interventional
Source	Neurana Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	July 31, 2017
Completion date	January 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06059677` - Cannabis Consumption and Driving Impairment Assessment on a Closed Course	Phase 2
Enrolling by invitation	`NCT05537116` - Evaluation of an Interactive Mobile Phone-Based Brief Intervention to Reduce Substance-Impaired Driving	N/A
Completed	`NCT03169855` - Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability
Recruiting	`NCT06111989` - Fitness to Drive Among Stroke Patients
Completed	`NCT04587609` - Reducing Cell Phone Use While Driving Among High Risk UBI Auto Policy Holders	N/A
Completed	`NCT03656029` - Dose-response of Cannabis and Driving	Phase 2
Completed	`NCT04330196` - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.	N/A
Completed	`NCT04948385` - Driving Performance After Deep Sedation for Outpatient Endoscopy	Phase 4
Completed	`NCT03335735` - Smartphone-paired Breathalyzers and Loss- and Gain-framed Texts for Reducing Drinking and Driving	N/A
Not yet recruiting	`NCT05703360` - Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance	N/A
Active, not recruiting	`NCT03581058` - Neural Correlates of Driving and Cannabis	Phase 1
Withdrawn	`NCT05273658` - Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests	Phase 1/Phase 2
Completed	`NCT04648735` - Driving Evaluation and Fitness for Persons With Cognitive Impairments	N/A
Completed	`NCT03195608` - Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease	N/A